A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
Genital herpes (HSV-2) is the most common cause of genital sores worldwide, and the presence
of genital sores is a significant risk factor for becoming infected with HIV. This study will
test the effectiveness of twice-daily dosing of acyclovir, a commonly prescribed anti-herpes
drug, in preventing HIV infection in HSV-2 infected women who sleep with men (WSM) and men
who sleep with men (MSM).
Study hypothesis: Given that genital herpes is a significant risk factor to HIV acquisition,
twice-daily HSV-2 suppressive therapy - 400 mg of acyclovir - will prevent HIV infection
among high risk, HSV-2 seropositive WSM and MSM.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) National Institute of Mental Health (NIMH) National Institute on Drug Abuse (NIDA)